Crossmark

Troponin testing—risk stratification to stratified medicine

Crossref DOI link: https://doi.org/10.1038/nrcardio.2015.157

Published Online: 2015-10-06

Published Print: 2015-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Newby, L. Kristin

Ohman, E. Magnus
License Information

Text and Data Mining valid from 2015-10-06
More Information

Article History

First Online: 6 October 2015

Competing interests

: L.K.N. has consulted for American College of Cardiology, American College of Physicians, American Heart Association, AstraZeneca, BioKier, CAMC Health Education & Research Institute, CardioDx Inc., Cubist Pharmaceuticals, Daiichi Sankyo, Eli Lilly & Company, Genentech, INC Research, JAHA, Janssen Pharmaceutical Products, Medscape LLC, Merck & Co., MetroHealth System, NIH, Philips, Roche Diagnostic Corp., Society of CV Patient Care, and VoxMedia; and receives salary support from Bristol Myers Squibb, GlaxoSmithKline, Google Life Sciences, MURDOCK study, and PCORI. E.M.O. has consulted for Abiomed, AstraZeneca, Daiichi Sankyo, Eli Lilly & Company, Gilead Sciences, Janssen Pharmaceuticals, Pozen Inc., Sanofi Aventis, The Medicines Company, and WebMD; and has received research grants from Daiichi Sankyo, Eli Lilly & Company, and Gilead Sciences.